Selective Androgen Receptor Modulator — Not Recommended
Matrix Advisory
SARMs are not recommended. Source data indicates poor risk-to-reward. Testosterone under medical supervision is the safer, more effective option.
LGD-4033 (Ligandrol) is a selective androgen receptor modulator (SARM) originally developed for muscle wasting and osteoporosis. It is one of the more potent SARMs in terms of lean mass gains but causes severe hormonal suppression. Source assessment: "Garbage." The risk-to-reward ratio does not justify use when supervised testosterone protocols exist.
Binds selectively to androgen receptors in muscle and bone, stimulating anabolic activity. Theoretically tissue-selective, but in practice LGD-4033 causes significant suppression of natural testosterone, FSH, and LH — often as severe as traditional anabolics — while delivering inferior results.
For Reference Only
Matrix does not recommend LGD-4033. These doses are provided solely for harm-reduction awareness. Testosterone under medical supervision is the preferred protocol.
| Parameter | Details |
|---|---|
| Starting Dose | 5 mg daily |
| Moderate Dose | 10 mg daily |
| Route | Oral |
| Cycle Length | 6–8 weeks |
| Suppression | Severe — significant HPTA shutdown even at low doses |
Mandatory Requirements
If used despite this advisory, the following are non-negotiable:
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any protocol.